FDA Advances Real-Time Clinical Trials: AI Pilot Program and Call for Comments
Updated: Jul 23
On April 29, 2026, the U.S. Food and Drug Administration (FDA) announced major steps
toward implementing real-time clinical trials, alongside a new pilot program on AI-
enabled optimization of early-phase studies.
This article summarizes the initiative and highlights the associated Request for
Information (RFI) currently open for stakeholder input.
Overview
Authority | U.S. Food and Drug Administration (FDA) |
Date | April 29, 2026 |
Focus | Real-time clinical trials & AI-enabled trial optimization |
Type | Pilot Program + Request for Information (RFI) |
Deadline for comments | May 29, 2026 |
Status: Closed
What are “real-time clinical trials”?
Real-time clinical trials represent a shift away from traditional, static study designs
toward continuous, data-driven trial management.
In conventional clinical trials:
data are collected and analyzed in predefined intervals
protocol adjustments are limited and often delayed
decisions are typically made after interim or final analyses
In contrast, real-time clinical trials aim to:
integrate continuous data streams (e.g. electronic health records, wearable
devices, digital endpoints)
enable ongoing data analysis during the trial
support adaptive decision-making in near real time
dynamically adjust aspects such as:
patient cohorts
dosing strategies
recruitment criteria
This approach is closely linked to:
adaptive trial designs
Bayesian methodologies
AI/ML-based analytics
AI pilot program and Request for Information
As part of this broader initiative, the FDA is launching a pilot program focused on AI-
enabled optimization of early-phase clinical trials.
The accompanying RFI (published April 29, 2026) seeks input on:
use of AI for dose selection and escalation
optimization of trial design and cohort management
integration of real-time data into decision-making
data quality, validation, and regulatory considerations
risks and limitations of AI-driven approaches
Key timeline
May 29, 2026 – Deadline for submission of comments
July 2026 – FDA intends to publish final selection criteria
August 2026 – Planned completion of pilot program selections
Why this matters
The initiative signals a significant regulatory direction toward:
continuous, adaptive clinical development models
increased acceptance of AI-supported trial methodologies
potential evolution of evidence generation standards
For sponsors, this could mean:
faster and more efficient early-phase development
greater flexibility in trial execution
but also higher expectations regarding:
data integrity
model transparency
regulatory justification of adaptive decisions
Who should consider responding?
This RFI is particularly relevant for:
pharmaceutical and biotech companies running Phase I/II trials
organizations developing AI-based trial optimization tools
CROs and technology providers
experts in biostatistics, adaptive design, and AI/ML
Practical implications
Companies should consider:
whether their current development programs could transition toward real-time
or hybrid designs
internal capabilities for continuous data integration and analysis
governance models for AI-supported decision-making
readiness for increased regulatory scrutiny in this area
Providing input at this stage offers an opportunity to shape the pilot program, influence future regulatory expectations and address practical implementation challenges early
Support with stakeholder responses
We support organizations in:
assessing the relevance of regulatory initiatives
identifying strategic opportunities and risks
preparing structured and impactful submissions to authorities
Note
We continuously monitor FDA, EMA, and other regulatory developments.
Check back regularly for updates on ongoing consultations and emerging regulatory
trends.